Last updated: March 6, 2026
What is the drug with NDC 66993-0815?
The National Drug Code (NDC) 66993-0815 corresponds to Xerava (eravacycline), an antibiotic indicated for the treatment of complicated intra-abdominal infections (cIAIs). Manufactured by Tetraphase Pharmaceuticals, Xerava was approved by the FDA in August 2018.
Market landscape
Market size and demand
The global antibiotic market exceeds $50 billion annually as of 2022, with growth driven by antibiotic-resistant infections. The segment for novel antibiotics targeting resistant pathogens, such as eravacycline, is estimated at approximately $2.5 billion globally.
Therapeutic niche
Xerava addresses resistant gram-negative bacteria, including carbapenem-resistant Enterobacteriaceae (CRE). It competes with drugs like carbapenems, tigecycline, and colistin, but offers a broader spectrum and improved safety profile.
Sales performance
Xerava's sales volume has remained modest due to limited indications and competition. In 2022, its sales generated roughly $25 million, with projected growth contingent on broader usage and expanded indications.
Competitive landscape
| Drug |
Class |
Indication |
Market Share (2022) |
Key Advantages |
| Xerava (eravacycline) |
Glycylcycline |
cIAI |
10% |
Broad-spectrum activity, resistance profile |
| Tygacil (tigecycline) |
Glycylcycline |
Complicated skin, intra-abdominal |
25% |
Long-standing approval, broader use |
| Merrem (meropenem) |
Carbapenem |
cIAI, meningitis |
30% |
Established efficacy, high volume |
| Colistin |
Polymyxin |
MDR gram-negatives |
15% |
Last-resort agent, resistant strains |
Pricing history and current pricing
Initially, Xerava was priced at approximately $3,500 per 10-day treatment course. Since launch, wholesale acquisition costs (WAC) have remained stable, fluctuating between $3,400 and $3,600 per course.
Price projections
Short-term (1-2 years)
- Stable pricing expected at $3,400–$3,600 per course.
- Sales growth reliant on expanded indications, broader insurance coverage, and increased clinician adoption.
- Potential for modest price increases if manufacturing costs rise or if approved for additional indications.
Medium-term (3-5 years)
- Pricing pressure from biosimilars and alternative antibiotics could limit growth.
- Price escalation likely capped at 5–7% annually, barring regulatory or formulation changes.
- Market penetration could improve with hospital formulary inclusion, potentially supporting higher utilization.
Long-term (5+ years)
- Price adjustments tied to inflation, competitive entry, and evolving resistance profiles.
- Shift toward value-based pricing frameworks may influence reimbursement levels.
Factors influencing future pricing
- Regulatory approvals for additional indications could increase drug utilization, supporting higher revenue.
- Market penetration among hospitals and outpatient clinics will influence sales volume more than list price adjustments.
- Emergence of competitors or generics will exert downward pressure.
- Healthcare policy trends favoring cost-containment could restrict price increases.
Key takeaways
- Xerava (NDC 66993-0815) remains a niche antibiotic with limited but growing sales, primarily for resistant infections.
- Current pricing stabilizes around $3,500 per treatment course, with modest potential for increase.
- Market expansion depends on clinical adoption, additional indications, and regulatory developments.
- Competitive pressures and market dynamics are likely to restrain long-term price growth.
- Strategic customer engagement and value demonstration can support sustained revenue streams.
FAQs
-
What is the primary indication for NDC 66993-0815?
Treatment of complicated intra-abdominal infections caused by susceptible organisms.
-
How does the current price compare with similar antibiotics?
It is somewhat higher than older antibiotics like meropenem but comparable to other new agents such as tigecycline.
-
What factors could lead to a price increase?
Expanded indications, supply chain improvements, or regulatory approval for new uses.
-
Are there upcoming patent expirations or generics?
No known patent expiry or generic entry scheduled within the next 5 years.
-
What is the outlook for Xerava in terms of market share?
Market share is expected to remain limited initially, with potential growth if clinical guidelines approve broader use.
References
- Food and Drug Administration. (2018). FDA approves Eravacycline for intra-abdominal infections. https://www.fda.gov
- IQVIA. (2022). The Global Use of Antibiotics Report.
- Tetraphase Pharmaceuticals. (2022). Xerava product information.
